Go Prime
New Research on Neoantigens and Tumor-targeting T-cells Marks Paradigm Shift in Countering Solid Tumors
2021-11-19
Following Two Years of Promising RNAi Collab, Novo Nordisk Decides to Acquire Dicerna for $3.3 Billion
2021-11-18
With New Funding, ACELYRIN Licenses First Therapeutic and Leaps into Late-Stage Trials for Autoimmune Diseases
2021-11-17
Scientists Engineer RNA Switches for Targeted Delivery of Gene Therapy and RNA Therapeutics
2021-11-07